Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer

1 Dec 2021

Abstract excerpt

This study addresses the roles of nuclear receptor corepressor 2 (NCOR2) in prostate cancer (PC) progression in response to androgen deprivation therapy (ADT). Reduced NCOR2 expression significantly associates with shorter disease-free survival in patients with PC receiving adjuvant ADT. Utilizing the CWR22 xenograft model, we demonstrate that stably reduced NCOR2 expression accelerates disease recurrence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to FOXO transcription factor regulation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34910907
DOI: 10.1016/j.celrep.2021.110109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancerPMID 34910907Read ↗

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancerSemantic proximity Read ↗

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate CancerSemantic proximity Read ↗

Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer ProgressionSemantic proximity Read ↗

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerSemantic proximity Read ↗

CtBP2 modulates the androgen receptor to promote prostate cancer progression.Semantic proximity Read ↗

Polycomb-mediated silencing in neuroendocrine prostate cancerSemantic proximity Read ↗

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

LNCaP Atlas: Gene expression associated with in vivoprogression to castration-recurrent prostate cancerSemantic proximity Read ↗

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancerSemantic proximity Read ↗

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2Semantic proximity Read ↗

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13Semantic proximity Read ↗

The lncRNA <i>DRAIC</i> / <i>PCAT29</i> Locus Constitutes a Tumor-Suppressive NexusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.